Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254202 | 0.98 | ALDH1A1 (0.46) | ALDH1A1EPHX2FOLH1RIMKLANAALAD2 | |
| SCHEMBL2244920 | 0.98 | ALDH1A1 (0.46) | ALDH1A1EPHX2FOLH1RIMKLANAALAD2 | |
| SCHEMBL4621858 | 0.93 | FOLH1 (0.41) | EPHX2FOLH1RIMKLANAALAD2LMNA | |
| SCHEMBL29501687 | 0.84 | EPHX2 (0.53) | ALDH1A1EPHX2FOLH1RIMKLANAALAD2 | |
| SCHEMBL5670486 | 0.79 | SMN1; SMN2 (0.44) | ALDH1A1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL2247731 | 0.79 | KMT2A (0.41) | ALDH1A1EPHX2LMNABLMSMN1; SMN2 | |
| SCHEMBL10935609 | 0.78 | FOLH1 (0.53) | EPHX2FOLH1RIMKLANAALAD2 | |
| SCHEMBL10935612 | 0.78 | FOLH1 (0.53) | EPHX2FOLH1RIMKLANAALAD2 | |
| SCHEMBL2254208 | 0.78 | EPHX2 (0.42) | ALDH1A1EPHX2LMNABLMSMN1; SMN2 | |
| SCHEMBL2244922 | 0.78 | EPHX2 (0.42) | ALDH1A1EPHX2LMNABLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | ALDH1A1 991/4885EPHX2 1904/4885FOLH1 17/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | ALDH1A1 991/4885EPHX2 1904/4885FOLH1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.